Fulvic Acid Supplementation and Metabolic Syndrome
Metabolic Syndrome
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 18 years - 65 years
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 60 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Fulvic acid is a naturally occurring compound derived from the decomposition of organic matter in soil over long periods. Fulvic acid complexes, such as MLG-50 (MLG-50® Mineral Logic, Kalamazoo, Michigan), offer a highly concentrated, water-soluble form of fulvic acid that contains over 70 trace minerals and elements. Our preclinical studies have found that a soil derived organic mineral complex rich in fulvic acid prevented the high fat diet induced hyperglycemia, endothelial dysfunction, liver injury, endotoxemia, and gut dysbiosis induced by high-fat feeding in rats. We propose to examine the efficacy of fulvic acid (both 50 mg and 100 mg daily for 12 weeks) in the mitigation of symptoms related to metabolic syndrome.
Read the full description
Clinical trials examining the efficacy of fulvic acid on health parameters are scarce. However, shilajit, a natural substance rich in fulvic acid, was shown to reduce triglycerides, cholesterol, and increase HDL cholesterol as well as antioxidant status in healthy college students (n=30) after 45 days of supplementation (2 g daily). However, this quasi-experimental trial did not randomize participants into experimental groups, and causality cannot be evaluated. A 2018 review of the peer-reviewed literature on the therapeutic potential of fulvic acid concluded that although the available research is minimal, there was 'substantial evidence' to pursue fulvic acid research for improving biomarkers linked to chronic inflammatory diseases.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- metabolic syndrome or prediabetes
Exclusion Criteria:
- pregnant or nursing
- multiple medications to treat obesity, heart disease, thyroid conditions, cancer
- smokers
- competing athletes
- vegetarians
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Random assignment
- Masking
- Double masked
Fulvic acid 50
50 mg
Dietary Supplement: fulvic acid
Fulvic acid 100
100 mg
Dietary Supplement: fulvic acid
Placebo
cornstarch
Other: Placebo
fulvic acid DIETARY_SUPPLEMENT
50 mg
fulvic acid DIETARY_SUPPLEMENT
100 mg
Placebo OTHER
cornstarch
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
girth
Time frame: from enrollment to 6 week and to 12 week
waist circumference in cm
hypertension
Time frame: from enrollment to 6 week and to 12 week
diastolic and systolic blood pressure
hyperglycemia
Time frame: from enrollment to 6 week and to 12 week
fasting blood glucose
hypertriglyceridemia
Time frame: from enrollment to 6 week and to 12 week
fasting blood triglycerides
cholesterol
Time frame: from enrollment to 6 week and to 12 week
fasting blood HDL cholesterol
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
PBC 850 N 5th StreetPhoenix, Arizona, United StatesRecruiting
Study team and timeline
- Lead sponsor
- Arizona State University
- Study start
- Nov 6, 2026 Estimated
- Primary completion
- Nov 15, 2027 Estimated
- Study completion
- Nov 15, 2027 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Evaluation of Fulvic Acid Supplementation for the Attenuation of Symptoms Associated With Metabolic Syndrome
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026
